Table_1_Exploring the predictive properties of the Hayes Ability Screening Index subtest background information in identifying individuals with MBID among in-patients with SUD.docx

IntroductionFor individuals with substance use disorder (SUD), mild to borderline intellectual disability (MBID) goes undetected in treatment clinics. The Hayes Ability Screening Index (HASI) has been found to be a valid, time-saving screening instrument for MBID in SUD treatment. MBID can have significant implications for treatment planning and outcomes. Therefore, it is important to have methods for the early recognition of these comorbid conditions. Because of less sensitivity to recent or ongoing substance use, the HASI subtest background information may be particularly valuable as an early screening of MBID. The main aim was to investigate the convergent, predictive, and discriminant validity of the HASI subtest background information in identifying in-patients with SUD as MBID or non-MBID.MethodsEighty-four in-patients with SUD aged 19–64 participated in this multicentre study. MBID was diagnosed according to the ICD-10 using WAIS-IV, Vineland II, and self-reported childhood learning difficulties.ResultsThe main finding was that, among the HASI subtests, background information was the strongest predictor. A HASI background information cut between 6 and 7 showed a sensitivity of 78% and a specificity of 72%.ConclusionThe HASI subtest background information has acceptable convergent, predictive, and discriminant validity as a screening for MBID among in-patients in SUD treatment.</p

Number of subjects classified as active TB and LTBI by IL-1ra, IL-2 and IP-10.

<p>Number of subjects classified as active TB and LTBI by IL-1ra, IL-2 and IP-10.</p

Markers differentiating between active and latent TB infection.

<p>Nil levels (pg/mL) of IL-1β, IL-1ra, IL-9 and IL-17a in patients with active TB (ATB), latent TB infection (LTBI) and in QFT negative controls (QFT negative). The horizontal lines show the median values. Mann-Whitney U test was used for comparison between groups. Brackets represents statistically significant differences (p≤0.004).</p

Clinical characteristics of the study participants.

<p>Clinical characteristics of the study participants.</p

Markers differentiating TB infection from QFT negative controls.

<p>TB antigen stimulated background corrected (TBAg-Nil) levels of IL-1ra, IL-2, IP-10, IFN-γ, IL-13, IL-15, IL-17a and MCP-1 in patients with active TB (ATB), latent TB infected subjects with QFT result >0.70 IU/mL (LTBI QFT>0.7), subjects with QFT result in the borderline zone 0.35–0.70 IU/mL (LTBI QFT<0.7) and in QFT negative controls (QFT negative). The horizontal lines show the median values. Mann-Whitney U test was used for comparison between groups. The TBAg-Nil level of IP-10 and MCP-1 were excluded from statistical analyses when the LTBI and ATB groups were compared because high proportions of study subjects in both groups had levels above the UDL of the assay. Brackets represents statistically significant differences (p<0.005).</p

ROC curve analyses for differentiation between the QFT borderline group and QFT negative controls.

<p>ROC curve analyses for differentiation between the QFT borderline group and QFT negative controls.</p

Albrecht III. von Österreich (1349/50-1395), österreichischer Herzog

Kurzbiographie signiert mit J. v. W. Quelle: Dictionnaire historique de Moreri, reon par Dronet, Paris 1759. Teilnachlass: Kurzbiographie Umfang: 1 S. Datum: undatiert Archiv-Signatur: Astr.-NL-4.27

Basic and other measurements of radiation at station Barrow (2014-03)

Factors affecting on-scene time (linear mixed effect model) in acute myocardial infarction. (XLS 33 kb

Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer

<div><p>Introduction</p><p>The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The prognostic value of gene sets from commercial gene-expression assays were compared with proliferation markers.</p><p>Methods</p><p>Illumina WG6 mRNA microarray analysis was used to examine 94 fresh-frozen tumour samples from node-negative breast cancer patients. The patients were divided into low- and high-risk groups for distant metastasis based on the MammaPrint-related genes, and into low-, intermediate- and high-risk groups based on the recurrence score algorithm with genes included in Oncotype DX. These data were then compared to proliferation status, as measured by the mitotic activity index, the expressions of phosphohistone H3 (PPH3), and Ki67.</p><p>Results</p><p>Kaplan-Meier survival analysis for distant-metastasis-free survival revealed that patients with weak and strong PPH3 expressions had 14-year survival rates of 87% (<i>n</i> = 45), and 65% (<i>n</i> = 49, <i>p</i> = 0.014), respectively. Analysis of the MammaPrint classification resulted in 14-year survival rates of 80% (<i>n</i> = 45) and 71% (<i>n</i> = 49, <i>p</i> = 0.287) for patients with low and high risks of recurrence, respectively. The Oncotype DX categorization yielded 14-year survival rates of 83% (<i>n</i> = 18), 79% (<i>n</i> = 42) and 68% (<i>n</i> = 34) for those in the low-, intermediate- and high-risk groups, respectively (<i>p</i> = 0.52). Supervised hierarchical cluster analysis for distant-metastasis-free survival in the subgroup of patients with strong PPH3 expression revealed that the genes involved in Notch signalling and cell adhesion were expressed at higher levels in those patients with distant metastasis.</p><p>Conclusion</p><p>This pilot study indicates that proliferation has greater prognostic value than the expressions of either MammaPrint- or Oncotype-DX-related genes. Furthermore, in the subgroup of patients with high proliferation, Notch signalling pathway genes appear to be expressed at higher levels in patients who develop distant metastasis.</p></div

Long-term distant-metastasis-free survival curves according to PPH3 expression (A), classification by Oncotype DX RS (B), and classification by genes related to MammaPrint (C).

<p>Long-term distant-metastasis-free survival curves according to PPH3 expression (A), classification by Oncotype DX RS (B), and classification by genes related to MammaPrint (C).</p